Lamivudine

SKU: orb1310390

Description

Lamivudine

Research Area

Infectious Disease & Virology, Pharmacology & Drug Discovery, Protein Biochemistry

Key Properties

• CAS Number: 134678-17-4
• MW: 229.3
• Purity: >98%
• Formula: C₈H₁₁N₃O₃S
• SMILES: O=C1N([C@H]2O[C@@H](CO)SC2)C=CC(N)=N1
• Target: Inflammasome
• Solubility: Soluble in DMSO (up to 30 mg/ml)

Bioactivity

• In Vivo:
  Lamivudine exhibits selective inhibitory activity against deoxycytidine kinase, an unusual substrate for the non-natural L-isomer of dNTPs preferred by HBV polymerase. The anti-HBV activity of PCV is attributed to the broad substrate specificity of deoxycytidine kinase and an unusual substrate preference of HBV polymerase for the non-natural L-conformation of dNTPs. The anti-HBV efficacy of PCV appears to rely on multiple factors, including optimal phosphorylation (sufficient for antiviral activity but not cytotoxicity), the extended intracellular half-life of PCV-TP, and the ability of PCV-TP to inhibit the initiation of HBV RT as well as its RT and DNA polymerase activities. Combined use of Lamivudine and Cidofovir synergistically inhibits replication of duck hepatitis B virus and is more effective in reducing the persistent covalently closed circular (CCC) DNA form of DHBV than when used separately. In PBMCs, Lamivudine inhibits HIV-1 p24 antigen production with ED50s ranging from 0.07 μM to 0.2 μM.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

(-)-BCH-189; 3TC

Compound Identifiers

PubChem CID

60825